Skip to content

Study · Animal study (in vivo) · mouse · 2003

6 results

MTII-induced reduction of voluntary ethanol drinking is blocked by pretreatment with AgRP-(83-132).

Navarro M, Cubero I, Knapp DJ, Thiele TE

Neuropeptides1 Dec 2003Cited by 46 (Europe PMC)

PMID14698676 (opens in a new tab)DOI10.1016/j.npep.2003.10.003 (opens in a new tab)PepBankPUB-14698676
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In alcohol-preferring mice, central MTII (1.0 microg) reduced 8-h voluntary ethanol drinking.

    In plain wordsIn mice that prefer alcohol, MTII given into the brain reduced the amount of ethanol they drank.

    Peptide
    Melanotan II
    Outcome
    Decrease8-h ethanol drinking after central MTII
    Study

    mousen: not reported in source

    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    1.0 microg · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    MTII-induced (1.0 microg) reduction of 8-h ethanol drinking and food intake, consistent with a competitive antagonist action.
    1 context sentence
    Summary · context
    In alcohol preferring C57BL/6 mice with an established history of ethanol drinking, intracerebroventricular (i.c.v.) infusion of a 5.0 microg dose of agouti-related protein (AgRP)-(83-132), a non-selective MCR antagonist, has no effect on 8-h ethanol drinking or food intake.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In alcohol-preferring mice, central MTII (1.0 microg) reduced 8-h food intake.

    In plain wordsIn mice that prefer alcohol, MTII given into the brain reduced food intake.

    Peptide
    Melanotan II
    Outcome
    Decrease8-h food intake after central MTII
    Study

    mousen: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1.0 microg · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    MTII-induced (1.0 microg) reduction of 8-h ethanol drinking and food intake, consistent with a competitive antagonist action.
    1 context sentence
    Summary · context
    In alcohol preferring C57BL/6 mice with an established history of ethanol drinking, intracerebroventricular (i.c.v.) infusion of a 5.0 microg dose of agouti-related protein (AgRP)-(83-132), a non-selective MCR antagonist, has no effect on 8-h ethanol drinking or food intake.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice, pretreatment with the antagonist AgRP-(83-132) significantly blocked the MTII-induced reduction of 8-h ethanol drinking.

    In plain wordsIn mice, a melanocortin receptor blocker prevented MTII from lowering ethanol drinking.

    Peptide
    Melanotan II
    Outcome
    Not applicableBlockade of the MTII ethanol effect by AgRP-(83-132)
    Study

    mousen: not reported in source

    Comparator
    MTII without AgRP-(83-132) pretreatment
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.0 microg · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    However, pre-treatment with a 5.0 microg dose of (AgRP)-(83-132) significantly blocks MTII-induced (1.0 microg) reduction of 8-h ethanol drinking and food intake, consistent with a competitive antagonist action.
    2 context sentences
    Summary · context
    Additionally, the ability of (AgRP)-(83-132) to block the effects of MTII implies that MTII-induced reduction of ethanol drinking is receptor mediated.
    Summary · context
    In alcohol preferring C57BL/6 mice with an established history of ethanol drinking, intracerebroventricular (i.c.v.) infusion of a 5.0 microg dose of agouti-related protein (AgRP)-(83-132), a non-selective MCR antagonist, has no effect on 8-h ethanol drinking or food intake.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice, pretreatment with the antagonist AgRP-(83-132) significantly blocked the MTII-induced reduction of 8-h food intake.

    In plain wordsIn mice, a melanocortin receptor blocker prevented MTII from lowering food intake.

    Peptide
    Melanotan II
    Outcome
    Not applicableBlockade of the MTII food intake effect by AgRP-(83-132)
    Study

    mousen: not reported in source

    Comparator
    MTII without AgRP-(83-132) pretreatment
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    1.0 microg · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    However, pre-treatment with a 5.0 microg dose of (AgRP)-(83-132) significantly blocks MTII-induced (1.0 microg) reduction of 8-h ethanol drinking and food intake, consistent with a competitive antagonist action.
    1 context sentence
    Summary · context
    In alcohol preferring C57BL/6 mice with an established history of ethanol drinking, intracerebroventricular (i.c.v.) infusion of a 5.0 microg dose of agouti-related protein (AgRP)-(83-132), a non-selective MCR antagonist, has no effect on 8-h ethanol drinking or food intake.
  5. 05AnimalAnimal study (in vivo)Other

    In mice, central MTII did not alter blood ethanol levels 2 or 4 h after an intraperitoneal ethanol dose.

    In plain wordsIn mice, MTII given into the brain did not change blood ethanol levels after an ethanol injection.

    Peptide
    Melanotan II
    Outcome
    No significant changeBlood ethanol levels after central MTII
    Study

    mousen: not reported in source

    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    I.c.v. infusion of MTII does not cause alteration of blood ethanol levels 2- or 4-h following intraperitoneal (i.p.) injection of a 4.0 g ethanol/kg dose.
    1 context sentence
    Summary · context
    In alcohol preferring C57BL/6 mice with an established history of ethanol drinking, intracerebroventricular (i.c.v.) infusion of a 5.0 microg dose of agouti-related protein (AgRP)-(83-132), a non-selective MCR antagonist, has no effect on 8-h ethanol drinking or food intake.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In alcohol-preferring mice, intraperitoneal MTII (150 microg) reduced 8-h ethanol drinking.

    In plain wordsIn mice that prefer alcohol, MTII given by injection into the belly cavity reduced the amount of ethanol they drank.

    Peptide
    Melanotan II
    Outcome
    Decrease8-h ethanol drinking after intraperitoneal MTII
    Study

    mousen: not reported in source

    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    150 microg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Finally, when given in an i.p. injection, a 150 microg dose of MTII reduces 8-h ethanol drinking.
    1 context sentence
    Summary · context
    In alcohol preferring C57BL/6 mice with an established history of ethanol drinking, intracerebroventricular (i.c.v.) infusion of a 5.0 microg dose of agouti-related protein (AgRP)-(83-132), a non-selective MCR antagonist, has no effect on 8-h ethanol drinking or food intake.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.